The approval makes remibrutinib the first targeted therapy approved for symptomatic dermographism, expanding its indication beyond chronic spontaneous urticaria.
The novel GPR6 inhibitor met its primary endpoint in the phase 3 ARISE trial, achieving a statistically significant reduction in daily OFF time and demonstrating non-dopaminergic motor and ...
Serum ferritin threshold of less than or equal to 20ng/mL is suggested for children ages 9 months to 4 years. HealthDay News — In guidelines issued by the American Society of Hematology and published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results